JP2023538066A5 - - Google Patents
Info
- Publication number
- JP2023538066A5 JP2023538066A5 JP2023511906A JP2023511906A JP2023538066A5 JP 2023538066 A5 JP2023538066 A5 JP 2023538066A5 JP 2023511906 A JP2023511906 A JP 2023511906A JP 2023511906 A JP2023511906 A JP 2023511906A JP 2023538066 A5 JP2023538066 A5 JP 2023538066A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formulation
- subject
- day
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067786P | 2020-08-19 | 2020-08-19 | |
| US63/067,786 | 2020-08-19 | ||
| PCT/US2021/046591 WO2022040371A1 (en) | 2020-08-19 | 2021-08-19 | Methods for treating hypercholesterolemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538066A JP2023538066A (ja) | 2023-09-06 |
| JP2023538066A5 true JP2023538066A5 (cg-RX-API-DMAC10.html) | 2024-08-23 |
| JP7824930B2 JP7824930B2 (ja) | 2026-03-05 |
Family
ID=77693631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023511906A Active JP7824930B2 (ja) | 2020-08-19 | 2021-08-19 | 高コレステロール血症の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12472171B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4199928B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7824930B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN116056702B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022040371A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002053568A1 (en) * | 2000-12-28 | 2002-07-11 | Mochida Pharmaceutical Co., Ltd. | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds |
| US7838562B2 (en) * | 2003-06-24 | 2010-11-23 | University Of Connecticut | Methods of inhibiting vascular permeability and apoptosis |
| CN106278999B (zh) * | 2011-02-07 | 2019-10-25 | 比奥根Ma公司 | S1p调节剂 |
| BR112015001613B1 (pt) * | 2012-07-27 | 2021-02-23 | Biogen Ma Inc | compostos que são agentes de modulação de s1p e/ou agentes de modulação de atx, seus usos e composição farmacêutica |
| US20230390270A1 (en) * | 2020-08-19 | 2023-12-07 | Biogen Ma Inc. | Methods for treating remitting multiple sclerosis |
-
2021
- 2021-08-19 JP JP2023511906A patent/JP7824930B2/ja active Active
- 2021-08-19 EP EP21766793.0A patent/EP4199928B1/en active Active
- 2021-08-19 WO PCT/US2021/046591 patent/WO2022040371A1/en not_active Ceased
- 2021-08-19 US US18/021,654 patent/US12472171B2/en active Active
- 2021-08-19 CN CN202180050829.0A patent/CN116056702B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1225A (en) | Therapeutic combinations. | |
| JP2024540183A5 (cg-RX-API-DMAC10.html) | ||
| US8481570B2 (en) | 1-methylnicotinaide derivatives and formulations of treatment of lipoprotein abnormalities | |
| JP2022545835A5 (cg-RX-API-DMAC10.html) | ||
| US20220000824A1 (en) | Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid | |
| CA2387398C (en) | Novel combination of loteprednol and antihistamines | |
| JP2017078083A (ja) | 低用量トピラメート／フェンテルミン組成物およびその使用方法 | |
| JP2004522714A5 (cg-RX-API-DMAC10.html) | ||
| RU2012110592A (ru) | Соединения и способ снижения мочевой кислоты | |
| US11147781B2 (en) | Methods for alleviating statin myopathy | |
| JP2014507476A (ja) | 高尿酸血症および高尿酸血症関連代謝障害を治療するための方法および組成物 | |
| US10363235B2 (en) | Compositions comprising 15-HEPE and methods of treating or preventing fibrosis using same | |
| JP2024524273A5 (cg-RX-API-DMAC10.html) | ||
| RU2004115023A (ru) | Фапмацевтическая композиция, содержащая (r)-бикалутамид | |
| JP2009545546A (ja) | リウマチ性疾患の遅延放出型グルココルチコイド治療 | |
| JP2023538065A5 (cg-RX-API-DMAC10.html) | ||
| JP2010505866A5 (cg-RX-API-DMAC10.html) | ||
| JP2024520020A5 (cg-RX-API-DMAC10.html) | ||
| McKenney | Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction | |
| CN105343024B (zh) | 一种阿托伐他汀钙片剂及其制备方法 | |
| US12257228B2 (en) | Cardioversion methods using budiodarone | |
| JP7356968B2 (ja) | 心血管疾患に有用な医薬 | |
| WO2002045705A2 (en) | Regenaration of blood vessels | |
| JP2009539990A (ja) | Ｃｘｃｒ２またはｃｘｃｒ１とｃｘｃｒ２との両方のいずれかの選択的アンタゴニストの薬学的処方物および組成物ならびに炎症性障害を治療するためにそれらを使用する方法 | |
| AU2019276955A1 (en) | Combinations comprising tropifexor and cenicriviroc |